Daily Stock Analysis, GKOS, Glaukos Corp, priceseries

Glaukos Corp. Daily Stock Analysis
Stock Information
Open
71.69
Close
71.01
High
71.78
Low
70.16
Previous Close
71.63
Daily Price Gain
-0.62
YTD High
83.14
YTD High Date
Mar 26, 2019
YTD Low
50.60
YTD Low Date
Jan 3, 2019
YTD Price Change
17.26
YTD Gain
32.11%
52 Week High
83.14
52 Week High Date
Mar 26, 2019
52 Week Low
30.28
52 Week Low Date
Apr 25, 2018
52 Week Price Change
39.49
52 Week Gain
125.29%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 15. 2017
45.71
Apr 5. 2017
50.68
15 Trading Days
10.86%
Link
LONG
Jan 8. 2018
26.79
Jan 31. 2018
30.03
16 Trading Days
12.09%
Link
LONG
Apr 23. 2018
30.31
May 10. 2018
33.80
13 Trading Days
11.52%
Link
LONG
May 23. 2018
34.96
Jun 21. 2018
41.26
20 Trading Days
18.03%
Link
LONG
Aug 22. 2018
41.31
Sep 14. 2018
61.85
16 Trading Days
49.72%
Link
LONG
Nov 26. 2018
58.77
Dec 13. 2018
63.27
12 Trading Days
7.65%
Link
LONG
Jan 30. 2019
62.37
Feb 21. 2019
67.41
15 Trading Days
8.08%
Link
LONG
Mar 12. 2019
69.16
Mar 27. 2019
75.54
11 Trading Days
9.23%
Link
Company Information
Stock Symbol
GKOS
Exchange
NYSE
Company URL
http://www.glaukos.com
Company Phone
949-367-9600
CEO
Thomas William Burns
Headquarters
California
Business Address
229 AVENIDA FABRICANTE, SAN CLEMENTE, CA 92672
Sector
Equity
Industry Category
Health Services
Industry Group
Medical Instruments & Supplies
CIK
0001192448
About

Glaukos Corp. is an ophthalmic medical device company, which engages in the development and commercialization of products and procedures designed to transform the treatment of glaucoma. Its micro invasive glaucoma surgery procedures are designed to reduce intraocular eye pressure by improving aqueous outflow through the natural physiologic pathway. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill in July 1998 and is headquartered in San Clemente, CA.

Description

Glaukos Corporation, an ophthalmic medical technology company, focuses on the development and commercialization of products and procedures designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry with the goal of achieving intraocular pressure reduction; iStent Supra suprachoroidal micro-bypass stent, which is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. It markets its products through direct sales force in the United States and internationally, as well as through distribution partners in Europe, the Asia Pacific, and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.